Neophobia is not only avoidance: Improving neophobia tests by combining cognition and ecology

Psychologists and behavioural ecologists use neophobia tests to measure behaviours ranging from anxiety to predatory wariness. Psychologists typically focus on underlying cognitive mechanisms at the expense of ecological validity, while behavioural ecologists generally examine adaptive function but ignore cognition. However, neophobia is an ecologically relevant fear behaviour that arises through a cognitive assessment of novel stimuli. Both fields have accrued conflicting results using various testing protocols, making it unclear what neophobia tests measure and what correlations between neophobia and other traits mean. Developing cognitively and ecologically informed tests allows neophobia to be empirically evaluated where appropriate and controlled for where it interferes with other behavioural measures. We offer guidelines for designing tests and stress the need for interdisciplinary dialogue to better explore neophobia's proximate causes and ecological consequences.We would like to thank Alecia Carter for helpful discussion and comments on the manuscript and to thank two anonymous reviewers and the editor, Dr. Hofmann, for their thoughtful and insightful feedback. A.L.G. received generous support from the Gates-Cambridge Trust; A.T. is funded by a BBSRC David Phillips Fellowship (BB/H021817/1).This is the author accepted manuscript. The final version is available from Elsevier via http://dx.doi.org/10.1016/j.cobeha.2015.10.00

Ecological basis of coevolutionary history

Journal ArticleMacroevolutionary patterns are difficult to interpret because they are the product of a time scale so vast that deterministic and chance events are hard to distinguish. Although the macroevolutionary history of a group can be reconstructed from extant species, determining the ecological context in which that group evolved is a tall order. Ecology involves interactions between organisms and both the living and nonliving components of their environments

Sociotechnical Safeguards for Genomic Data Privacy

Recent developments in a variety of sectors, including health care, research and the direct-to-consumer industry, have led to a dramatic increase in the amount of genomic data that are collected, used and shared. This state of affairs raises new and challenging concerns for personal privacy, both legally and technically. This Review appraises existing and emerging threats to genomic data privacy and discusses how well current legal frameworks and technical safeguards mitigate these concerns. It concludes with a discussion of remaining and emerging challenges and illustrates possible solutions that can balance protecting privacy and realizing the benefits that result from the sharing of genetic information

Approaches to Carrier Testing and Results Disclosure in Translational Genomics Research

Background: Clinical genome and exome sequencing (CGES) is primarily used to address specific clinical concerns by detecting risk of future disease, clarifying diagnosis, or directing treatment. Additionally, CGES makes possible the disclosure of autosomal recessive and X-linked carrier results as additional secondary findings, and research about the impact of carrier results disclosure in this context is needed. Methods: Representatives from 11 projects in the clinical sequencing exploratory research (CSER) consortium collected data from their projects using a structured survey. The survey focused on project characteristics, which variants were offered and/or disclosed to participants as carrier results, methods for carrier results disclosure, and project?specific outcomes. We recorded quantitative responses and report descriptive statistics with the aim of describing the variability in approaches to disclosing carrier results in translational genomics research projects. Results: The proportion of participants with carrier results was related to the number of genes included, ranging from 3% (three genes) to 92% (4,600 genes). Between one and seven results were disclosed to those participants who received any positive result. Most projects offered participants choices about whether to receive some or all of the carrier results. There were a range of approaches to communicate results, and many projects used separate approaches for disclosing positive and negative results. Conclusion: Future translational genomics research projects will need to make decisions regarding whether and how to disclose carrier results. The CSER consortium experience identifies approaches that balance potential participant interest while limiting impact on project resources

Education and Electronic Medical Records and Genomics Network, Challenges and Lessons Learned from a Large-Scale Clinical Trial Using Polygenic Risk Scores

Polygenic risk scores (PRS) have potential to improve health care by identifying individuals that have elevated risk for common complex conditions. Use of PRS in clinical practice, however, requires careful assessment of the needs and capabilities of patients, providers, and health care systems. The electronic Medical Records and Genomics (eMERGE) network is conducting a collaborative study which will return PRS to 25,000 pediatric and adult participants. All participants will receive a risk report, potentially classifying them as high risk (∼2-10% per condition) for 1 or more of 10 conditions based on PRS. The study population is enriched by participants from racial and ethnic minority populations, underserved populations, and populations who experience poorer medical outcomes. All 10 eMERGE clinical sites conducted focus groups, interviews, and/or surveys to understand educational needs among key stakeholders—participants, providers, and/or study staff. Together, these studies highlighted the need for tools that address the perceived benefit/value of PRS, types of education/support needed, accessibility, and PRS-related knowledge and understanding. Based on findings from these preliminary studies, the network harmonized training initiatives and formal/informal educational resources

The Reckoning: The Return of Genomic Results to 1444 Participants Across the eMERGE3 Network

The goal of Electronic Medical Records and Genomics (eMERGE) Phase III Network was to return actionable sequence variants to 25,084 consenting participants from 10 different health care institutions across the United States. The purpose of this study was to evaluate system-based issues relating to the return of results (RoR) disclosure process for clinical grade research genomic tests to eMERGE3 participants

A Game Theoretic Approach to Balance Privacy Risks and Familial Benefits

As recreational genomics continues to grow in its popularity, many people are afforded the opportunity to share their genomes in exchange for various services, including third-party interpretation (TPI) tools, to understand their predisposition to health problems and, based on genome similarity, to find extended family members. At the same time, these services have increasingly been reused by law enforcement to track down potential criminals through family members who disclose their genomic information. While it has been observed that many potential users shy away from such data sharing when they learn that their privacy cannot be assured, it remains unclear how potential users’ valuations of the service will affect a population’s behavior. In this paper, we present a game theoretic framework to model interdependent privacy challenges in genomic data sharing online. Through simulations, we find that in addition to the boundary cases when (1) no player and (2) every player joins, there exist pure-strategy Nash equilibria when a relatively small portion of players choose to join the genomic database. The result is consistent under different parametric settings. We further examine the stability of Nash equilibria and illustrate that the only equilibrium that is resistant to a random dropping of players is when all players join the genomic database. Finally, we show that when players consider the impact that their data sharing may have on their relatives, the only pure strategy Nash equilibria are when either no player or every player shares their genomic data